Startup Funding News

Explore funding rounds, the companies behind them and the investors taking part.

Rounds
474
All time
Disclosed funding
$19.6B
401 disclosed amounts
Median round
$20M
Of disclosed amounts
474 rounds
Funding rounds
CompanyAmountRoundSectorCountryInvestorsAnnounced
MeatlyFoodtech · United KingdomCompany profile

Develops cultivated meat production technology

Develops cultivated meat production technology

£10.4MSeries ABiotech, FoodtechUnited KingdomInvestors
CellCentricBiotech · United KingdomCompany profile

Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma

Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma

$220MSeries DSeries C+BiotechUnited KingdomInvestors
Kanvas BiosciencesBiotech · United StatesCompany profile

Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy

Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy

$48MSeries ABiotechUnited StatesInvestors
LTZ TherapeuticsBiotech · United StatesCompany profile

LTZ Therapeutics develops cancer immunotherapies that target myeloid biology.

LTZ Therapeutics develops cancer immunotherapies that target myeloid biology.

$38MUndisclosedBiotechUnited StatesInvestors
Signadori BioBiotech · FranceCompany profile

Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage

Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage

€11.1MSeed+SeedBiotechFranceInvestors
Pacific HybreedAgritech · United StatesCompany profile

Develops high-performance hybrid oyster and clam seed to improve yield and resilience for shellfish farmers

Develops high-performance hybrid oyster and clam seed to improve yield and resilience for shellfish farmers

$1MSeedBiotech, AgritechUnited StatesInvestors
4D PathHealthtech · United StatesCompany profile

Digital biomarkers designed to predict cancer treatment response from routine biopsy images.

Digital biomarkers designed to predict cancer treatment response from routine biopsy images.

UndisclosedStrategicUndisclosedBiotech, HealthtechUnited StatesInvestors
Undisclosed
NavidenceHealthtech · United StatesCompany profile

Provides AI-native platform with standardized computable definitions of diseases and outcomes for real-world evidence research

Provides AI-native platform with standardized computable definitions of diseases and outcomes for real-world evidence research

UndisclosedStrategicUndisclosedBiotech, HealthtechUnited StatesInvestors
Latus Bio, Inc.Biotech · United StatesCompany profile

Engineers scalable AAV gene therapies for CNS and rare diseases including Huntington's disease and CLN2

Engineers scalable AAV gene therapies for CNS and rare diseases including Huntington's disease and CLN2

$97MSeries ABiotechUnited StatesInvestors
EnteroBiotixBiotech · United KingdomCompany profile

Develops full-spectrum microbiome therapeutics for gastrointestinal diseases including IBS

Develops full-spectrum microbiome therapeutics for gastrointestinal diseases including IBS

£19MSeries BBiotechUnited KingdomInvestors

Active investors in this selection

All investors →

Ranked by rounds participated in · All time

  1. 1
    RA Capital Management

    Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology

    22rounds
    3led
  2. 2
    Janus Henderson Investors

    Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics

    15rounds
    1led
  3. 3
    Eli Lilly and Company

    BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences

    15rounds
    0led
  4. 4
    ARCH Venture Partners

    Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences

    14rounds
    0led
  5. 5
    OrbiMed

    Star Therapeutics, Leal Therapeutics, Accro Bioscience

    11rounds
    1led

Latest digests

Archive →

Explore published rounds while the next edition is being prepared.

Browse rounds by topic

Research · October 2026

Nordic Foodtech Fund II pairs early capital with scientific expertise

An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.

Read the research →